Exchange Traded Concepts LLC Boosts Stake in Hologic, Inc. (NASDAQ:HOLX)

Exchange Traded Concepts LLC increased its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 21.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,303 shares of the medical equipment provider's stock after acquiring an additional 4,539 shares during the period. Exchange Traded Concepts LLC's holdings in Hologic were worth $1,563,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of HOLX. Venturi Wealth Management LLC raised its position in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares during the last quarter. Smithfield Trust Co grew its stake in shares of Hologic by 160.0% in the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after buying an additional 400 shares during the last quarter. Finally, Raiffeisen Bank International AG purchased a new stake in shares of Hologic in the 4th quarter worth approximately $49,000. Institutional investors own 94.73% of the company's stock.

Hologic Trading Up 0.8%

NASDAQ HOLX traded up $0.51 during trading hours on Friday, hitting $64.48. 5,564,249 shares of the company were exchanged, compared to its average volume of 2,349,728. The stock has a 50-day moving average price of $59.29 and a 200 day moving average price of $64.37. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.67. The stock has a market cap of $14.37 billion, a PE ratio of 27.21, a price-to-earnings-growth ratio of 2.36 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. The firm had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The company's quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.03 earnings per share. Analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on HOLX. Argus downgraded Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Raymond James Financial reaffirmed an "outperform" rating and issued a $71.00 target price (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Royal Bank Of Canada decreased their price target on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Finally, Morgan Stanley decreased their price target on Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Twelve equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $77.42.

Insider Activity

In other news, Director Martin D. Madaus purchased 5,445 shares of the stock in a transaction that occurred on Wednesday, May 7th. The stock was purchased at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the acquisition, the director now owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 1.88% of the company's stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.